ReviewSeminars in immunopathology2024
Causes and costs of global COVID-19 vaccine inequity.
Review in Seminars in immunopathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of gross domestic product with equitable access to childhood vaccines in 195 countries: a systematic review and meta-analysis.BMJ global health · 2025Pooled it
- Accelerated discovery of thermostable mRNA-lipid nanoparticle vaccines using data-efficient AI.Nature biotechnology · 2026Article
- Reaching the margins: examining equity in Indonesia's COVID-19 vaccination strategy.BMJ global health · 2026Review
- Global vaccine development.Nature medicine · 2026Review
- Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches.Developing world bioethics · 2026Article
- Equitable access to the COVID-19 vaccines in Africa (ECOVA) findings from a qualitative enquiry in Zimbabwe.Frontiers in health services · 2026Article
- Confronting the known unknown: historical lessons and future strategies for Disease X.Frontiers in public health · 2026Review
- COVID-19 vaccination rates as a proxy for health system resilience: implications of development disparities for cervical cancer control during the pandemic.Frontiers in medicine · 2026Article
- Nigeria's post-COVID-19 vaccine manufacturing ambitions: Opportunities and regional implications.Journal of public health in Africa · 2026Article
- Article
- Pandemic treaty textual analysis: ethics and public health implications.Journal of public health (Oxford, England) · 2025Article
- Establishing a Preparedness Program: Lessons From COVID-19 to Strengthen Global Strategies for Future Pandemics.Cureus · 2025Review
- WHO Pandemic Agreement: The need for scientific implementation.PLoS pathogens · 2025Article
- Trends and cross-country inequities by region, sex, age in the mortality, incidence, and disability-adjusted life years of COVID-19: Analysis from the Global Burden of Disease Study 2021.PLoS neglected tropical diseases · 2025Article
- De-risking vaccine development: lessons, challenges, and prospects.NPJ vaccines · 2025Review
- The cost of delivering COVID-19 vaccines in four districts in Malawi.Cost effectiveness and resource allocation : C/E · 2025Article
- Enhanced durability of a Zika virus self-amplifying RNA vaccine through combinatorial OX40 and 4-1BB agonism.JCI insight · 2025Article
- Antiviral Activity of Halogenated Compounds Derived from L-Tyrosine Against SARS-CoV-2.Molecules (Basel, Switzerland) · 2025Article
- Roles of mobile teams in tracing lost to follow-up clients: evidence from the optimization of COVID-19 vaccination uptake and routine immunization in Ekiti State.BMC health services research · 2025Article
- Balancing fairness and efficiency in dynamic vaccine allocation during major infectious disease outbreaks.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the rapid development of safe and effective COVID-19 vaccines and the widely recognized health and economic benefits of vaccination, there exist stark differences in vaccination rates across country income groups. While more than 70% of the population is fully vaccinated in high-income countries, vaccination rates in low-income countries are only around 30%. The paper reviews the factors behind global COVID-19 vaccine inequity and the health, social, and economic costs triggered by this inequity. The main contributors to vaccine inequity include vaccine nationalism, intellectual property rights, constraints in manufacturing capacity, poor resilience of healthcare systems, and vaccine hesitancy. Vaccine inequity has high costs, including preventable deaths and cases of illnesses in low-income countries, slow economic recovery, and large learning losses among children. Increasing vaccination rates in low-income countries is in the self-interest of higher-income countries as it may prevent the emergence of new variants and continuous disruptions to global supply chains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.